Analystreport

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $13.00 price target on the stock.

Marinus Pharmaceuticals, Inc.  (MRNS) 
Last marinus pharmaceuticals, inc. earnings: 11/6 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.marinuspharma.com/investor-relations